ClinicalTrials.gg

Program

Alprazolam

Also written as “Alprazolam Extended-Release 3 mg Tablets”, “Staccato alprazolam” and “alprazolam XR”.

Its studies are mostly in Anxiety Disorders · Panic Disorder · Seizures · Epilepsy · Asthma, led by 6 companies.

Furthest: phase 4, since Mar 5, 200826 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viatris120 open or runningphase 4since Mar 5, 2008Oct 26, 2005none ahead
Teva Pharmaceutical Industries60 open or runningphase 1since Jan 26, 2009Jan 26, 2009none ahead
GlaxoSmithKline30 open or runningphase 1since Nov 28, 2012Nov 28, 2012none ahead
Novartis20 open or runningphase 1since Jun 2, 2009Jun 2, 2009none ahead
Orion Corporation, Orion Pharma20 open or runningphase 1since Apr 8, 2009Apr 8, 2009none ahead
Nova Pneuma10 open or runningphase 1since Jan 17, 2008Jan 17, 2008none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Oct 26, 2005.

  1. Mar 5, 20083 phase 4 studies in Panic DisorderViatris · NCT00635531, NCT00635076, NCT00634790
  2. Mar 28, 20083 phase 1 studies in HealthyViatris · NCT00647894, NCT00650299, NCT00647634
  3. Dec 16, 2008Phase 1 study in PharmacokineticsViatris · NCT00810316 · 24 enrolled · Mexico
  4. Jan 26, 2009Teva Pharmaceutical Industries's first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00830024, NCT00829426
  5. Mar 10, 2009Phase 1 study in HealthyViatris · NCT00860119 · 23 enrolled · India
  6. Mar 18, 20092 phase 1 studies in HealthyTeva Pharmaceutical Industries · NCT00865761, NCT00865657
  7. Apr 8, 2009Orion Corporation, Orion Pharma's first studies: 2 phase 1 studies in HealthyNew to Orion Corporation, Orion PharmaOrion Corporation, Orion Pharma · NCT00878865, NCT00878514
  8. Jun 2, 2009Novartis's first studies: 2 phase 1 studies in Anxiety DisordersNew to NovartisNovartis · NCT00913341, NCT00912145
  9. Jan 7, 2010Phase 1 study in HealthyViatris · NCT01046162
  10. Aug 23, 20102 phase 1 studies in HealthyTeva Pharmaceutical Industries · NCT01188057, NCT01188031
  11. Apr 5, 2011Phase 1 study in Healthy SubjectsViatris · NCT01330472 · 16 enrolled · Singapore
  12. Nov 28, 2012GlaxoSmithKline's first study: phase 1 study in Anxiety DisordersNew to GlaxoSmithKlineGlaxoSmithKline · NCT01853956 · 28 enrolled
  13. Dec 6, 20122 phase 1 studies in Anxiety DisordersGlaxoSmithKline · NCT01745575, NCT01745562
  14. Aug 17, 2026Phase 4 study in Healthy Non-dependent, Recreational Sedative UsersViatris · NCT07777965 · 44 enrolled · United States

TargetBeta

“GABA-A receptor; anion channel positive allosteric modulator”ChEMBL 37, by rule

Other programs on the same 16 targets

ProgramCompanyFurthest phaseStudies
MidazolamrulePfizerphase 496
ciprofolruleHaisco Pharmaceutical Groupphase 436
brexanoloneruleSupernus Pharmaceuticalsphase 414
DiazepamruleAcorda Therapeuticsphase 39

Studies

All 26 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07777965Healthy Non-dependent, Recreational Sedative Users · United States4CompletedViatrisAug 31, 202644
NCT01745575Anxiety Disorders1CompletedGlaxoSmithKlineApr 5, 201026
NCT01745562Anxiety Disorders1CompletedGlaxoSmithKlineDec 17, 201028
NCT01853956Anxiety Disorders1CompletedGlaxoSmithKlineDec 10, 201028
NCT01330472Healthy Subjects · Singapore1CompletedViatrisJun 201116
NCT01188057Healthy · United States1CompletedTeva Pharmaceutical IndustriesAug 200640
NCT01188031Healthy · United States1CompletedTeva Pharmaceutical IndustriesJul 200640
NCT01046162Healthy1WithdrawnViatrisJul 22, 20100
NCT00913341Anxiety Disorders1CompletedNovartisNov 199130
NCT00912145Anxiety Disorders1CompletedNovartisFeb 199626
NCT00878865Healthy · Finland1CompletedOrion Corporation, Orion PharmaJun 200918
NCT00878514Healthy · Finland1CompletedOrion Corporation, Orion PharmaJun 200918
NCT00865761Healthy · United States1CompletedTeva Pharmaceutical IndustriesSep 200540
NCT00865657Healthy · United States1CompletedTeva Pharmaceutical IndustriesSep 200540
NCT00860119Healthy · India1CompletedViatrisOct 200923
NCT00830024Healthy · United States1CompletedTeva Pharmaceutical IndustriesJun 200536
NCT00829426Healthy · United States1CompletedTeva Pharmaceutical IndustriesJun 200532
NCT00810316Pharmacokinetics · Mexico1CompletedViatrisNov 200824
NCT00650299Healthy · United States1CompletedViatrisAug 200421
NCT00647634Healthy · United States1CompletedViatrisAug 200421
NCT00647894Healthy · United States1CompletedViatrisJan 200524
NCT00635531Panic Disorder · United States4TerminatedViatris16
NCT00635076Panic Disorder · United States4TerminatedViatris3
NCT00634790Panic Disorder · United States4TerminatedViatris49
NCT00603980Abuse Liability of Staccato Alprazolam · United States1CompletedNova PneumaJan 200931
NCT00245609Dental Anxiety · Germany, United Kingdom2CompletedViatris90

How it is read

Names in the registry

  • “Alprazolam”, 10 entries
  • “Alprazolam Extended-Release 3 mg Tablets”, 4 entries
  • “Staccato alprazolam”, 3 entries
  • “alprazolam XR”, 3 entries
  • “Staccato Alprazolam”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.